Skip to content

VitamIn and oXygen Interventions and Cardiovascular Events

Hyperoxia and Antioxidants During Major Non-cardiac Surgery and Risk of Cardiovascular Complications, a Blinded 2x2 Factorial Randomised Clinical Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03494387
Acronym
VIXIE
Enrollment
600
Registered
2018-04-11
Start date
2018-04-06
Completion date
2020-03-24
Last updated
2021-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Cardiac Complication

Keywords

Antioxidant, Hyperoxia, Troponin, MINS, Ascorbic acid, N-acetylcysteine

Brief summary

This study examines the risks and benefits of antioxidants and normal versus high inspiratory oxygen fraction during anaesthesia.

Detailed description

Adult patients with risk factors for developing postoperative cardiac complications will be enrolled in the study. The patients will be randomised to receiving antioxidants or placebo perioperatively and 30% or 80% inspiratory oxygen concentration during anaesthesia and 2 hours postoperatively. The primary outcome is MINS (myocardial injury after non-cardiac surgery). The antioxidants are ascorbic acid (vitamin C) 3 grams intravenously preoperatively and N-acetylcysteine 100 milligrams/kilogram body weight intravenous infusion for 4 hours, starting at the same time as anaesthesia. The study is a long-term follow-up study of the risk of mortality, MI and readmissions performed at 1 year after inclusion of the last patient. Two other follow-up studies are planned: One investigation of ischaemic troponin elevations defined as peak troponin levels above the internationally defined thresholds without extracardiac causes; another investigating the intervention effects in the subgroup of patients undergoing vascular surgery with specific emphasis on episodes of intraoperative hypotension within the following thresholds: MAP below 70 mmHg, 65 mmHg, 60 mmHg and 55 mmHg.

Interventions

DRUGOxygen

80% versus 30% inspiratory oxygen concentration

DRUGAntioxidants

Antioxidants versus placebo

Sponsors

University Hospital Bispebjerg and Frederiksberg
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

All of the listed criteria (1.-4.) must be met. 1. Age 45 years or above 2. Elective or acute surgery in general anaesthesia 3. Scheduled for abdominal, orthopaedic, or vascular surgery with expected surgery duration of one hour or more. 4. Fulfil any 1 of the following 5 criteria: 1. \- History of coronary artery disease including angina 2. \- History of stroke 3. \- Undergoing vascular surgery 4. \- History of peripheral arterial disease 5. \- Any 2 of the following 8 criteria: i. Acute surgery ii. Current or previous daily smoking iii. History of hypertension iv. Diabetes mellitus requiring medical treatment v. History of transient cerebral ischemia vi. Plasma creatinine \>175 µM vii. Age 70 years or above viii. History of congestive heart failure

Exclusion criteria

1. Surgery within 30 days prior to operation 2. Arterial oxygen saturation below 90% without oxygen supplementation 3. Inability to give informed consent 4. Drug allergy towards any of the drugs involved in the trial 5. Previous treatment with bleomycin 6. Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Myocardial injury after non-cardiac surgery (MINS)30 daysTroponin measurement the first 3 postoperative days. Assessed by area under the curve.

Secondary

MeasureTime frameDescription
MortalityDuring the study period until completion of last visit of last patientAssessed as time to event analysis
Non-fatal myocardial infarctionDuring the study period until completion of last visit of last patientAssessed as time to event analysis
Non-fatal Serious Adverse EventDuring the study period until completion of last visit of last patientAssessed as time to event analysis

Other

MeasureTime frameDescription
Surgical site infectionAssessed at postoperative day 30Infection in surgical area as defined by the Center for Disease Control
Acute kidney injuryAssessed at postoperative day 30Acute kidney injury as defined Kidney Disease Improving Global Outcomes guidelines
PneumoniaAssessed at postoperative day 30Pneumonia as defined by the Center for Disease Control
SepsisAssessed at postoperative day 30Sepsis as defined by the joint task force by the European Society of Intensive Care Medicine and the Society of Critical Care Medicine
Acute respiratory failureAssessed at postoperative day 30Acute respiratory failure defined as the need for controlled ventilation or oxygen saturation of 900% or less despite of oxygen therapy

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026